A global consortium of academic researchers, pharmaceutical companies, and philanthropic organizations has released three free, open-source AI tools designed to help scientists develop new treatments for Alzheimer's disease and other neurodegenerative conditions. The Consortium for Biomedical Research and Artificial Intelligence in Neurodegeneration (C-BRAIN), founded by Washington University School of Medicine in St. Louis, announced the tools at the Alzheimer's Association International Conference in London on July 13, 2026.

Why Does Alzheimer's Drug Development Need AI Help?

The challenge is stark: more than 99% of Alzheimer's drug candidates fail in clinical trials, despite decades of research. The problem isn't a lack of scientific knowledge. Instead, vital insights remain scattered across millions of published papers, massive datasets, and unpublished research results that researchers struggle to synthesize. This fragmentation means scientists often repeat failed experiments or miss connections that could lead to breakthroughs.

C-BRAIN's mission is to build what its leaders call an "AI Biomedical Research Scientist" that works alongside human researchers to connect these dots. The consortium includes 17 members spanning academia, industry, and philanthropy, including Bristol Myers Squibb, Johnson & Johnson, Sanofi, and the Alzheimer's Drug Discovery Foundation.

What Are the Three AI Tools C-BRAIN Released?

The consortium released three interrelated tools, all freely available to biomedical researchers working in neurodegeneration:

• AI Literature and Data Synthesis: Uses advanced retrieval methods to synthesize Alzheimer's and neuroscience literature, helping researchers evaluate hypotheses faster than manual review would allow.
• Dark Data Analyzer: Surfaces insights from unpublished data and negative results contributed by academic and pharmaceutical members, helping researchers avoid repeating failed experiments and learn from what didn't work.
• Reviewer Three: A critical reasoning agent that provides scientifically grounded, peer review-style feedback on grant proposals, manuscripts, and experimental designs.

The tools were built in part using resources from the National Artificial Intelligence Research Resource (NAIRR) Pilot program, an initiative of the National Science Foundation and Microsoft. They were developed by Adith Boloor, a staff AI scientist with the WashU Digital Intelligence and Innovation Accelerator; Ade Ojewole, C-BRAIN's Chief Technology Officer; and Eric Landsness, an assistant professor of neurology at WashU Medicine.

How Does C-BRAIN Keep Data Private While Sharing Insights?

A key innovation of C-BRAIN's design is its federated structure, which allows members to keep full control of their own data. Proprietary and unpublished pharmaceutical data can inform the tools without being exposed or transferred to other parties. Additionally, a "scientist-in-the-loop" approach keeps human researchers involved at every stage of the process, ensuring that AI-driven discoveries can be verified and reproduced by other scientists.

"It is antithetical to science that we would develop AI tools that function as an uninterpretable black box. By delivering an entirely open system, scientists worldwide can look at the code, analyze it, test it, improve on it, and collectively find where the flaws are. These tools are built for scientists, by scientists, and are owned by the scientific community," said Randall J. Bateman, the Charles F. and Joanne Knight Distinguished Professor of Neurology at WashU Medicine and director and founder of C-BRAIN.

Randall J. Bateman, Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine

This transparency is crucial. Rather than hiding the AI's decision-making process in what researchers call a "black box," C-BRAIN's open-source approach allows the global scientific community to scrutinize, test, and improve the tools collectively.

Why Are Pharmaceutical Companies and Nonprofits Both Interested?

The consortium appeals to its diverse members for different reasons. For pharmaceutical partners like Bristol Myers Squibb, C-BRAIN creates a rare pre-competitive space where companies can sharpen the foundational science that precedes drug development. This means identifying the right biological targets and disease mechanisms before companies invest their expertise and resources into developing treatments.

"By bringing together advanced computational tools, unique datasets, and deep scientific expertise, C-BRAIN is helping the field ask better questions and move with speed toward answers on neurodegenerative diseases. Partnerships like this are central for us at Bristol Myers Squibb to ensure we have the right tools in place as we explore both symptomatic and disease-modifying approaches, with the ultimate ambition to bring medicines to patients faster," stated Richard Hargreaves, Senior Vice President of the Neuroscience Thematic Research Center at Bristol Myers Squibb.

Richard Hargreaves, Senior Vice President of the Neuroscience Thematic Research Center at Bristol Myers Squibb

For philanthropic backers like the Alzheimer's Drug Discovery Foundation, the appeal is the long-term vision: a set of openly available, non-commercial tools that any approved biomedical researcher can use to advance the field without commercial constraints.

How to Access and Use C-BRAIN's Tools

• Registration Process: Biomedical researchers working in neurodegeneration can register for approval by contacting C-BRAIN directly through the consortium's website.
• Cost: All three tools are freely available to approved researchers, with no licensing fees or subscription costs required.
• Public Demonstration: A demonstration of the tools' capabilities is publicly available on the consortium's website, allowing researchers to preview functionality before registering for full access.

Bateman anticipates that C-BRAIN's AI Scientist will accelerate the pace of discovery many times over by boosting the efficiency and effectiveness of Alzheimer's disease and neurodegeneration research. The convergence of drug developers, philanthropic and patient-advocacy groups, and researchers who have fought these diseases for decades, all equipped with these AI tools, represents a significant shift in how neurodegenerative disease research is conducted.

"Aligning drug developers, philanthropic and patient-advocacy groups, and researchers and doctors who have fought these diseases for decades, and giving them these AI tools, is how we deliver on our promise to patients and the people who care for them," Bateman explained.

Randall J. Bateman, Charles F. and Joanne Knight Distinguished Professor of Neurology at Washington University School of Medicine